EUCTR2004-000240-25-IT进行中（未招募）不适用
An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study toevaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide inpatients with essential hypertension.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,685
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patiens with essential hypertensioEUCTR2004-000240-25-SEovartis Sverige AB2,685
进行中（未招募）
1 期
An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patiens with essential hypertensioEUCTR2004-000240-25-SKovartis s.r.o.
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.hypertensionEUCTR2008-001609-40-DKovartis Pharma Services AG1,611
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.hypertensionEUCTR2008-001609-40-GRovartis Pharma Services AG1,611
进行中（未招募）
不适用
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionhypertensionEUCTR2008-001609-40-FIovartis Pharma Services AG1,611